IgG4-rich reactive lymphoid hyperplasia of the lacrimal gland. Orbit 2020 Aug;39(4):285-288
Date
11/15/2019Pubmed ID
31724473DOI
10.1080/01676830.2019.1687735Scopus ID
2-s2.0-85075233546 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
We describe an otherwise healthy 24-year-old woman with reactive lymphoid hyperplasia of one lacrimal gland. She was found to have modest elevation of serum IgG4 and high density of IgG4+ plasma cells in her lacrimal gland, ranging from 40% to 60% of IgG+ plasma cells. The patient transiently responded to systemic corticosteroids before treatment with rituximab. IgG4-rich reactive lymphoid hyperplasia of the lacrimal gland is neither an established part of IgG4-related disease spectrum nor a known precursor lesion to lymphoma. Although there is a plausible risk of transforming to IgG4-related disease or to lymphoma, the biological potential and natural history of IgG4-rich reactive lymphoid hyperplasia remains to be determined.
Author List
Mancera N, Bajric J, Margo CEMESH terms used to index this publication - Major topics in bold
Antineoplastic Agents, ImmunologicalFemale
Humans
Immunoglobulin G
Lacrimal Apparatus Diseases
Plasma Cells
Pseudolymphoma
Rituximab
Tomography, X-Ray Computed
Young Adult
